Contrarius Investment Management LTD Biogen Inc. Transaction History

Contrarius Investment Management LTD

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 12, 2021	SELL	$259.0 - $414.71 $4.46 Million - $7.14 Million	-17,224 Closed	0 $0
Q1 2021 May 07, 2021	BUY	$242.95 - $284.63 $4.18 Million - $4.9 Million	17,224 New	17,224 $4.82 Million
Q4 2018 Feb 05, 2019	SELL	$278.5 - $352.75 $6.78 Million - $8.58 Million	-24,329 Closed	0 $0
Q3 2018 Nov 09, 2018	BUY	$293.51 - $383.83 $1.96 Million - $2.56 Million	6,681 Added 37.86%	24,329 $8.6 Million
Q2 2018 Aug 08, 2018	BUY	$257.52 - $306.91 $1,545 - $1,841	6 Added 0.03%	17,648 $5.12 Million
Q1 2018 May 02, 2018	BUY	$260.13 - $367.91 $634,457 - $897,332	2,439 Added 16.04%	17,642 $4.83 Million
Q4 2017 Feb 09, 2018	SELL	$307.64 - $344.58 $30.8 Million - $34.5 Million	-100,137 Reduced 86.82%	15,203 $4.84 Million
Q3 2017 Nov 08, 2017	BUY	$281.15 - $329.69 $32.4 Million - $38 Million	115,340	115,340 $36.1 Million

1,037

126M

1.13M

1.43M

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $21.1B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

Get notified when there are updates to the investment portfolio of Contrarius Investment Management LTD, based on Form 13F filings with the SEC.

Stay updated on Contrarius Investment Management LTD with notifications on news.